AzTrials
AzTrials

Laparoscopic CholecystectomyNCT05099250

Adding Magnesium Sulfate to Bupivacaine in Ultrasound Guided Paravertebral Block for Laparoscopic Cholecystectomy

A study testing Bupivacain, magnesium sulfate and saline in people with Laparoscopic Cholecystectomy, run by Mansoura University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Laparoscopic cholecystectomy is one of the most commonly performed minimally invasive surgical procedures for the treatment of symptomatic cholelithiasis Laparoscopic cholecystectomy has clear benefits when compared with open surgery, but post-operative pain is still a common complaint after it The patient undergoing… Read more about this study

Who is it for?
Ages 20 to 60 years
Conditions the study is for
Laparoscopic Cholecystectomy
What is being tested?
Bupivacain, magnesium sulfate and saline
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
50 participants
Where
1 siteEgypt
Study dates
15 Jul 2019to 15 Feb 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • patients scheduled for elective laparoscopic cholecystectomy were enrolled in this study

Who cannot join

  • patient refusal to participate,
  • Sever renal or cardiac illness,
  • Pulmonary diseases as emphysema or chronic obstructive pulmonary disease
  • Neuromuscular diseases (as myopathies and myasthenia gravies), -Hematological diseases, bleeding or coagulation abnormality,
  • Psychiatric diseases,
  • Local skin infection and sepsis at site of the block,
  • Known hypersensitivity to the study drugs, and Severe chest wall deformity, e.g. scoliosis.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Marwa Ibrahim Mohamed Abdo

    Al Mansurah

Other trials in Egypt

About this study

Official title: Evaluation of the Efficacy of Adding Magnesium Sulfate as an Adjuvant to Bupivacaine in Bilateral Ultrasound Guided Paravertebral Block for Laparoscopic Cholecystectomy

Laparoscopic cholecystectomy is one of the most commonly performed minimally invasive surgical procedures for the treatment of symptomatic cholelithiasis Laparoscopic cholecystectomy has clear benefits when compared with open surgery, but post-operative pain is still a common complaint after it The patient undergoing laparoscopic cholecystectomy suffers from severe post-operative pain, it can prolong hospital stay and lead to increased morbidity Post-operative laparoscopic cholecystectomy pain can be relieved by some methods pre-emptive analgesic regimens containing ketamine, regional anesthesia techniques including paravertebral block Paravertebral Block is a regional anesthetic and analgesic technique which may offer comparable analgesic effectiveness with minimal side effects Paravertebral Block has been used a lot in the last two decades, several studies show its efficacy in, thoracoscopic surgery and laparoscopic cholecystectomy .Paravertebral block is the technique of injecting local anesthetic adjacent to the thoracic vertebra close to where the spinal nerves emerge from the intervertebral foramina, resulting in ipsilateral somatic and sympathetic nerve blockade in multiple dermatomes above and below the site of injection .

Bupivacaine is a local anesthetic that is capable of producing prolonged high quality analgesia in the postoperative period It is shown that paravertebral block using bupivacaine significantly reduces pain score Many drugs have been used as adjuvants to local anesthetic in peripheral nerve block in order to augment its analgesic effect and prolong the duration of the block such as opioids and magnesium sulfate Many studies have reported safety and efficacy of adding magnesium to local anesthetics in various regional anesthetic procedures, such as intrathecal, epidural, caudal, brachial plexus blocks and intravenous regional anesthesia. Magnesium play a major role in central nociceptive transmission, modulation and sensitization of acute and chronic pain states due to its antagonistic effect on N-methyl D-aspartate (NMDA) receptors .

Read the detailed description

Patients and Methods

Patients:

This is a blind prospective randomized controlled study that will be conducted for one year in Mansoura university hospitals after approval from the Institutional Research Board (IRB), Faculty of Medicine, Mansoura University, patients will be interviewed and written informed consents will be obtained. This study will include 26 patients of American Society of Anesthesiologists physical status grade I and grade II, of both sexes, aged between 20-60 years who will be scheduled for laparoscopic cholecystectomy.

Sample size calculation A Priori G-power analysis was done to estimate study sample size. A power of 90% was estimated with type I error of 0.05 to get an analgesic duration difference between groups of approximately 30% to yield of total sample size of 50 cases (25cases per group).

Randomization:

Fifty patients (number = 50) had laparoscopic cholecystectomy and bilateral paravertebral block during the study period. These patients were randomly allocated to undergo bilateral ultrasound guided paravertebral block. The groups allocated are concealed in sealed opaque envelopes which were not opened until patient consent was obtained.

The two groups were:

  1. Control group: Bupivacaine Group (B group) Number=25 : Included patients who received 17 mL of 0.25% bupivacaine + 3 mL mili saline 0.9% in a total volume of 20 ml on each side.
  2. Magnesium Group (M group) N=25 :

Included patients who received 17 mL of 0.25% bupivacaine + 3 mL of 75 mg milgram magnesium sulfate diluted in 0.9% saline in a total volume of 20 ml on each side.

All patients were performed by the same anesthetic team with standard procedure.

Methodology:

Anesthetic Management:

Preoperative Management:

All patients will be visited a day prior to surgery and will be assessed preoperatively by History, physical examination and laboratory evaluation (complete blood picture, coagulation profile, liver function and renal function tests). The study protocol and paravertebral block procedure will be explained to all patients. All patients will be familiar with the use of 0-10 visual analogue scale score identifying 0 as no pain and 10 as worst imaginable pain. Patient fast 6-8 hour before the time of surgery.

On arrival of the patient to the operating room routine monitoring will be applied, peripheral intravenous cannula 20 gauge will be inserted and 0.9% saline will be started to be infused. All patients will be premedicated using midazolam 0.03 mg/kg kilo intravenous.

Paravertebral block will be performed before induction of general anesthesia.

Technique of ultrasound guided paravertebral nerve block:

  • Standard precautions for the performance of ultrasound-guided nerve blocks will be followed which include continuous routine monitoring, the skin overlying the injection site should be free of signs of infection and prepped with an antiseptic solution.
  • Patient will lay in the lateral position, paravertebral block will be done using a 38 mm mile meter broadband linear array ultrasound probe.The probe surface in contact with the skin should be covered with a sterile adhesive dressing.
  • A sagittal paramedian view of the paravertebral space will be obtained by applying the probe at a point 2.5 cm centimeter lateral to the tip of the spinous process in a vertical orientation, The fifth thoracic vertebral level will be identified by palpating and counting down from the seventh cervical body.
  • The midpoint of the transducer will be aligned midway between the transverse processes of thoracic vertebra T5 and T6, 4 ml of 1 % lidocaine was injected subcutaneously at the puncture site,and 22 gauge spinal needle will be inserted in an in plane approach in a cephalad orientation and will be advanced perpendicularly to all skin planes under direct vision to puncture the superior costotransverse ligament where a click may be appreciated.
  • Following negative aspiration, 1-2 ml of study solution will be injected to verify correct position of the needle tip and the rest of study solution will be injected in fractioned doses following intermittent aspiration between the superior costotransverse ligament and the parietal pleura which will be displaced anteriorly by the injectate.
  • Similar approach will be used for the paravertebral block on the other side.
  • Sensory block over the area of surgical incision will be confirmed by loss of cold sensation using an alcohol swab and pinprick sensation using a 23 G gauge needle every 3 mint until 15 min after injection of the study solutions and before starting general anesthesia.

General Anesthesia:

General Anesthesia will be induced using intravenous propofol (2-3 mg/kg), fentanyl IV (1µ/kg) microgram/kilo and atracurium besylate (0.6 mg/kg) to facilitate intubation. Then patient will be mechanically ventilated using a volume control mode with Tv 6-8ml/kg, respiratory rate 10-14 breath/min and I.E. ratio 1:2 to maintain Etco2 35-40 mmHg mli mercury. Anesthesia will be maintained using minimum alveolar concentration of isoflurane 1.2% and 60% air in O2 mixture with top up dose of atracurium. Intraoperative IV fluids will be given per body weight and according to intraoperative loss.

All patients will be extubated at the end of surgery after neuromuscular reversal with administration of neostigmine (0.05 mg/kg) and IV atropine (0.02 mg/kg) and fulfilling the criteria of extubation. The duration of the surgery will be recorded.

Monitoring:

Intra-operative assessment

  • In operating room, monitoring will be achieved by five lead electro cardi gram, oxygen saturation and non-invasive mean arterial blood pressure.
  • Base line values of heart rate, oxygen saturation and non-invasive mean arterial blood pressure will be collected before and after paravertebral block, just after induction of anesthesia, at skin incision, then recording will be done every 15 mint till the end of the first hour and then every 30min interval till the end of surgery.
  • Sensory block onset will be defined when the patient subjectively evaluate the intensities of both cold and pinprick sensations in the blocked side decrease 75 % or more.
  • Duration of surgery will be defined as the time from induction to discharge from the operating room will be recorded.
  • In case of increased in intra-operative systolic blood pressure and heart rate of more than 20% of baseline for longer than 5min, incremental doses of fentanyl IV 0.5µ/kg will be given and the case will be excluded.

Postoperative Assessment:

  • On admission into the post operative care unit, all vital data \& hemodynamics (non-invasive mean arterial blood pressure, heart rate, and oxygen saturation) will be recorded at 1, 2, 6, 12 and 24 hrs. postoperative
  • Post-operative complications will be recorded including post-operative nausea and vomiting treated by metoclopramide, hypotension treated by phenylephrine drops, bradycardia treated by atropine or pneumothorax, respiratory depression and chest pain, respiratory depression is defined as respiratory rate less than 8 per minute or oxygen saturation below 90%.

Statistical analysis The statistical analysis of data will be done by using excel program for figures and Statistical Package for Social Science program version 22. To test the normality of data distribution Kolmogorov- Smirnov test will be done only significant data revealed to be nonparametric. Unpaired student-t test will be used for comparisons of numerical variables between-group, if its assumptions were fulfilled, otherwise for non-parametric; the Mann-Whitney test will be used. The description of data done in the form of mean (±SD) stander division for quantitative data and frequency and proportion for qualitative data. Any difference or change showing probability (P) less than 0.05 will be considered statistically significant at confidence interval 95%.

Being tested
Bupivacain, magnesium sulfate, saline
Keywords
paravertebral block laparoscopic cholecystectomy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BupivacainDrug

    Also called Control group: Bupivacaine Group (B group, Saline

    local anesthetic agent

  • magnesium sulfateDrug

    Also called Magnesium Group (M group), saline

    In the central nervous system , it has depressant effects, by antagonism at NMDA receptors and through inhibition of release of catecholamines

  • salineOther

    medical solution

Study groups in NCT05099250
Study groupRoleWhat they receive
Control group: Bupivacaine Group (B group)Placebo comparatorIncluded patients who received 17 mL of 0.25% bupivacaine + 3 mL saline 0.9% in a total volume of 20 ml on each side
Receives: Drug: Bupivacain; Other: saline
Magnesium Group (M group)Active comparatorIncluded patients who received 17 mL of 0.25% bupivacaine + 3 mL of 75 mg magnesium sulfate diluted in 0.9% saline in a total volume of 20 ml on each side.
Receives: Drug: Bupivacain; Drug: magnesium sulfate; Other: saline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. change of postoperative pain intensity

    measured by visual analogue scale . All patients were familiar with the use of 0 -10 visual analogue scale identifying 0 as no pain and 10 as worst imaginable pain.

    Pain intensity was assessed at rest and during cough with VAS score at 1, 2, 6, 12 and 24 hours postoperatively.

    When the patients experienced pain (VAS score > 3), A bolus dose of IV morphine 0.02 mg/kg was administered till visual analogue scale score ≤ 4 was attained.

    Measured: first 24 hours postoperatively

Secondary outcomes (2)
  1. change opioid consumption in first 24 hours

    measured by recording the time of first post-operative administration of morphine.

    Also, the total dose of post-operative morphine (mg) consumed in the first postoperative 24 hours was calculated in both groups.

    Measured: first 24 hours postoperatively

  2. change of analgesia duration

    duration of analgesia was defined as the time from applying the block till the first intravenous morphine administration

    Measured: first 24 hours postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Oct 2021
  2. Study start15 Jul 2019
  3. Primary completion10 Sep 2020
  4. Study completion15 Feb 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Sequential
Model description
The groups allocated are concealed in sealed opaque envelopes which were not opened until patient consent was obtained. The two groups were: 1. Control group: Bupivacaine Group (B group) N=25 : Included patients who received 17 mL of 0.25% bupivacaine + 3 mL saline 0.9% in a total volume of 20 ml on each side. 2. Magnesium Group (M group) N=25 : Included patients who received 17 mL of 0.25% bupivacaine + 3 mL of 75 mg magnesium sulfate diluted in 0.9% saline in a total volume of 20 ml on each side. All patients were performed by the same anesthetic team with standard procedure.
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05099250
Sponsor's protocol ID
MS/18.01.12
Status last verified
Oct 2021
First submitted
19 Aug 2021
Last updated
8 Nov 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Agarwal A, Batra RK, Chhabra A, Subramaniam R, Misra MC. The evaluation of efficacy and safety of paravertebral block for perioperative analgesia in patients undergoing laparoscopic cholecystectomy. Saudi J Anaesth. 2012 Oct-Dec;6(4):344-9. doi: 10.4103/1658-354X.105860.

    PubMed 23493523
  • Bisgaard T, Klarskov B, Rosenberg J, Kehlet H. Characteristics and prediction of early pain after laparoscopic cholecystectomy. Pain. 2001 Feb 15;90(3):261-269. doi: 10.1016/S0304-3959(00)00406-1.

    PubMed 11207398
  • Lau H, Brooks DC. Predictive factors for unanticipated admissions after ambulatory laparoscopic cholecystectomy. Arch Surg. 2001 Oct;136(10):1150-3. doi: 10.1001/archsurg.136.10.1150.

    PubMed 11585507
  • Salihoglu Z, Yildirim M, Demiroluk S, Kaya G, Karatas A, Ertem M, Aytac E. Evaluation of intravenous paracetamol administration on postoperative pain and recovery characteristics in patients undergoing laparoscopic cholecystectomy. Surg Laparosc Endosc Percutan Tech. 2009 Aug;19(4):321-3. doi: 10.1097/SLE.0b013e3181b13933.

    PubMed 19692881
  • Davies RG, Myles PS, Graham JM. A comparison of the analgesic efficacy and side-effects of paravertebral vs epidural blockade for thoracotomy--a systematic review and meta-analysis of randomized trials. Br J Anaesth. 2006 Apr;96(4):418-26. doi: 10.1093/bja/ael020. Epub 2006 Feb 13.

    PubMed 16476698
  • Klein SM, Bergh A, Steele SM, Georgiade GS, Greengrass RA. Thoracic paravertebral block for breast surgery. Anesth Analg. 2000 Jun;90(6):1402-5. doi: 10.1097/00000539-200006000-00026.

    PubMed 10825328
  • Soni AK, Conacher ID, Waller DA, Hilton CJ. Video-assisted thoracoscopic placement of paravertebral catheters: a technique for postoperative analgesia for bilateral thoracoscopic surgery. Br J Anaesth. 1994 Apr;72(4):462-4. doi: 10.1093/bja/72.4.462.

    PubMed 8155453
  • Cheema SP, Ilsley D, Richardson J, Sabanathan S. A thermographic study of paravertebral analgesia. Anaesthesia. 1995 Feb;50(2):118-21. doi: 10.1111/j.1365-2044.1995.tb15092.x.

    PubMed 7710020
  • Kopacz DJ, Allen HW, Thompson GE. A comparison of epidural levobupivacaine 0.75% with racemic bupivacaine for lower abdominal surgery. Anesth Analg. 2000 Mar;90(3):642-8. doi: 10.1097/00000539-200003000-00026.

    PubMed 10702451
  • Bilgin M, Akcali Y, Oguzkaya F. Extrapleural regional versus systemic analgesia for relieving postthoracotomy pain: a clinical study of bupivacaine compared with metamizol. J Thorac Cardiovasc Surg. 2003 Nov;126(5):1580-3. doi: 10.1016/s0022-5223(03)00701-3.

    PubMed 14666036
  • Akhondzade R, Nesioonpour S, Gousheh M, Soltani F, Davarimoghadam M. The Effect of Magnesium Sulfate on Postoperative Pain in Upper Limb Surgeries by Supraclavicular Block Under Ultrasound Guidance. Anesth Pain Med. 2017 Jun 10;7(3):e14232. doi: 10.5812/aapm.14232. eCollection 2017 Jun.

    PubMed 28924560
  • Lee AR, Yi HW, Chung IS, Ko JS, Ahn HJ, Gwak MS, Choi DH, Choi SJ. Magnesium added to bupivacaine prolongs the duration of analgesia after interscalene nerve block. Can J Anaesth. 2012 Jan;59(1):21-7. doi: 10.1007/s12630-011-9604-5. Epub 2011 Oct 20.

    PubMed 22012543
  • Choyce A, Peng P. A systematic review of adjuncts for intravenous regional anesthesia for surgical procedures. Can J Anaesth. 2002 Jan;49(1):32-45. doi: 10.1007/BF03020416.

    PubMed 11782326
  • Haefeli M, Elfering A. Pain assessment. Eur Spine J. 2006 Jan;15 Suppl 1(Suppl 1):S17-24. doi: 10.1007/s00586-005-1044-x. Epub 2005 Dec 1.

    PubMed 16320034

Questions about this trial

What is this clinical trial studying?

A study testing Bupivacain, magnesium sulfate and saline in people with Laparoscopic Cholecystectomy, run by Mansoura University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

change of postoperative pain intensity (time frame: first 24 hours postoperatively). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05099250, which also lists 14 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in